What Is PT-141?
PT-141 is a melanocortin peptide fragment supplied by Peptegrity for research and educational purposes. This page provides a factual educational overview of PT-141, including its classification, biological target, research background, terminology and published study context. It is not a product page and does not provide dosing instructions, treatment recommendations or personal-use guidance.
Type of compound
PT-141, also known as bremelanotide, is a synthetic peptide analogue classified as a melanocortin receptor agonist [5]. It is a cyclic heptapeptide lactam derivative of the naturally occurring alpha-melanocyte-stimulating hormone [5].
Biological target and mechanism
The compound functions by non-selectively activating melanocortin receptors, specifically the MC3R and MC4R subtypes within the central nervous system [5]. Research investigates how this activation influences pathways involved in physiological arousal responses [4].
Research background
PT-141 was developed through research originating from the modification of the peptide melanotan II, specifically to remove the tanning properties while isolating other physiological effects [5]. Investigations have focused on its pharmacodynamic profile and its potential to modulate various neurological pathways in controlled research environments [1][3].
Current research and development status
Bremelanotide has been the subject of extensive clinical development programs aimed at assessing its safety and efficacy in specific research cohorts [1][4]. While some formulations have received regulatory approval in specific jurisdictions for targeted use, it remains a compound of ongoing scientific interest in wider clinical research contexts [3].
Published research context
Published literature covers a range of scientific inquiries including safety and tolerability studies [1][2]. Research has also explored the interaction of the compound with other substances [2] and its administration efficacy in controlled trial settings [4].
Relevant terminology
Melanocortin receptors are a class of G protein-coupled receptors involved in a wide array of biological functions, including energy homeostasis and physiological signaling. As an agonist, PT-141 is designed to bind to these receptors to initiate a biological response rather than simply occupying the receptor site.
Storage and handling terminology
In laboratory research settings, peptides such as PT-141 are typically stored as lyophilized powders in a controlled, moisture-free environment at temperatures of -20°C or lower to maintain structural integrity. Reconstitution should be performed according to established laboratory protocols using sterile, recommended solvents to ensure stability for in vitro or in vivo experimentation.
Testing and Certificate of Analysis (COA)
A Certificate of Analysis (COA) is a document issued by quality control laboratories that verifies the purity and composition of the chemical compound. For research-grade PT-141, the COA typically includes data from analytical techniques such as High-Performance Liquid Chromatography (HPLC) to confirm purity levels and Mass Spectrometry (MS) to verify molecular weight.
Regulatory status
PT-141 is intended strictly for research and development purposes and is not a product for human therapeutic use unless explicitly approved by the relevant local regulatory health authority. Researchers must adhere to local regulations regarding the purchase, handling, and laboratory use of investigational peptides.
This page is for research and educational purposes only. It is not intended to provide medical advice, dosing instructions, or treatment recommendations, and does not represent any product as approved to diagnose, treat, cure or prevent any disease. Compounds described here may be investigational or unapproved medicines; regulatory status is summarised for information only.
Frequently asked questions
What is PT-141?
PT-141, or bremelanotide, is a synthetic peptide that acts as a melanocortin receptor agonist [5].
How is PT-141 classified?
It is classified as a melanocortin receptor agonist, derived from the structure of alpha-melanocyte-stimulating hormone [5].
What is the regulatory status of PT-141?
PT-141 is an investigational compound; while it has been studied in clinical trials, it is intended only for laboratory research purposes [3][4].
Where is PT-141 research published?
Research findings are available in various scientific journals, including studies on clinical safety and pharmacodynamic profiles [1][2][3].
References
- 1.Safety Profile of Bremelanotide Across the Clinical Development ProgramPubMed
- 2.Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female ParticipantsScienceDirect
- 3.Bremelanotide: First ApprovalPubMed
- 4.A Placebo-controlled, Randomized, Parallel Group, Dose-finding Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With FSAD (Female Sexual Arousal Disorder) and/or HSDD (Hypoactive Sexual Desire Disorder)ClinicalTrials.gov
- 5.Bremelanotide | C50H68N14O10 | CID 9941379PubChem
